

### **REMARKS**

The present response is submitted in reply to the Final Office Action issued on January 22, 2008. The Applicants thank the Examiner for the withdrawal of the previous rejections under 35 USC Sections 101 and 112. Claims 3-7 are pending in this application, all of which have been rejected. By the present response, claim 8 has been added which is supported by claim 7 and claims 4 and 5 have been canceled. No new matter has been added.

Reconsideration is respectfully requested in light of the following remarks.

#### **Rejection of claims 3-7 under 35 U.S.C. 112, first and/or second paragraphs**

Claim 5 has been rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the Applicants regard as the invention. In particular, the Examiner states that within the structure given in the claim, the "O" at the 14 position of the ring structure does not have a substituent indicating the addition of a group. The Examiner further states that claim 6 further limits claim 5 and the "O" at the 14 position is connected to a group or formula. The Examiner requests that the Applicants complete claim 5 by putting another "R" group to exemplify the invention. The Examiner has interpreted the "O" being at the 14 position being open to contain any group or formula.

Claims 3-7 have been rejected under 35 U.S.C. 112, first paragraph, on the basis that the specification does not reasonably provide enablement for treating diseases mediated by *Helicobacter pylori* and in particular chronic gastritis. The Examiner further states that the specification does not enable any person skilled in the art to which it

pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The Applicants respectfully request that the aforementioned rejections be withdrawn, as discussed below.

Regarding the indefinite rejection of claim 5, the Applicants submit that claim 5 recites a pleuromutilin in more detail in that a structural part thereof is unambiguously defined. The Applicants submit that neither a pleuromutilin, nor a structural part thereof, should be considered to be indefinite since one skilled in the art would clearly be aware what a pleuromutilin is. There are numerous discussions of pleuromutilins and pleuromutilin antibiotics on the Internet. For example, reference is made to [http://en.wikipedia.org/wiki/Category:Pleuromutilin\\_antibiotics](http://en.wikipedia.org/wiki/Category:Pleuromutilin_antibiotics); <http://www.nabriva.com/programs/pleuromutilins>; <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1489758>, among many others.

Therefore, withdrawal of this rejection is requested.

Regarding the rejection of claims 1-7 as being indefinite, at page 5 of the Final Office action, section 2, the Examiner addresses the presence or absence of working examples. The Applicants draw the Examiner's attention to paragraph [0209] of the publication of the present application where the specification confirms that the compounds of the present invention show activity against strains of *H.pylori*, e.g., even against strains of *H.pylori* which are resistant against treatment with known pharmaceuticals and which are known to be useful in the treatment of diseases caused by *H.pylori* infections, e.g., metronidazol resistant strains. Furthermore, the Applicants

respectfully request the Examiner's consideration of the "TABLE TEST" (paragraph [0288]) from which it is evident that compounds of the present invention work in known and acknowledged test systems for determining the activity of *H.pylori* strains, even much better than the known pharmaceuticals against *H.pylori* caused diseases such as metronidazol and tetracycline.

The Applicants note that clearly the effect of pleuromutilins against *H.pylori* activity was unknown at the priority date of the present invention and thus it is not possible that pleuromutilin treatment against *H.pylori* infection could have been mentioned in Malfertheiner, et al. (or Rokkas, et al.), as discussed by the Examiner in the Final Office action. However, the Applicants respectfully submit that in Malfertheiner, et al. and Rokkas, et al. it is clearly taught that a compound which inhibited *H.pylori* activity is appropriate for the treatment of peptic ulcer diseases and gastric adenocarcinoma. That *H.pylori* activity is responsible for peptic ulcer diseases and gastric cancers is also evident from, e.g., Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 11<sup>th</sup> Edition, Section VI, pages 978-979 (copy enclosed). Moreover, it is shown in *Milestones in Drug Therapy*, Macrolide Antibiotics, pages 53, 66 and 71 (copy enclosed) that clarithromycin may be used for *H.pylori* associated gastroduodenal diseases (page 66, first 2 lines) and that clarithromycin has been used for the treatment and prevention of the recurrence of gastroduodenal ulcers caused by *H.pylori* because clarithromycin shows strong antibacterial activity against *H.pylori* (page 66, lines 7-11). Therefore, if a compound shows activity against *H.pylori* it would be evident to one skilled in the art that such compound may be used against diseases which are caused by *H.pylori*.

The Applicants respectfully disagree with the Examiner's position that *in vitro* data is insufficient to show patentability. It is known that for treatment of a disease caused by bacteria, the activity of the corresponding bacteria must be influenced, in the present case inhibited, and that is what the compounds of the present invention do. In particular, they inhibit the activity of the *H.pylori* strains which is thoroughly supported by data. Clinical data can only be provided after long troublesome clinical trials, which may preclude the ability to maintain secrecy of the patent prior to filing.

It is also submitted that one skilled in the art would be immediately aware how to use a compound for the treatment of diseases which are caused by *H.pylori*, namely, according to the experience with other compounds which are active against *H.pylori* via analogous handling.

It is again noted that the presently claimed invention has been deemed patentable in the corresponding European application. Although it is appreciated that the Examiner is not obligated to consider the patentability from a foreign patent office, the Applicants wish to bring this to the Examiner's attention.

In view of the above arguments and amendments, withdrawal of the rejections and objections is respectfully requested.


#### **Conclusion**

In light of the foregoing claims and arguments, it is believed that the present application is in condition for allowance, and such action is earnestly solicited. The Examiner is invited to call the undersigned if there are any remaining issues to be discussed which could expedite the prosecution of the present application.

Respectfully submitted,

Date: July 8, 2009

D. Peter Hochberg Co., L.P.A.  
1940 E. 6<sup>th</sup> St. – 6<sup>th</sup> Floor  
Cleveland, OH 44114  
(216) 771-3800

By:   
D. Peter Hochberg  
Reg. No. 24,603

*Gilman's*  
The  
Pharmacological  
Basis of  
THERAPEUTICS

*eleventh edition*

*Brunton*  
*with L. Parker*

twice-daily dosing with a proton pump inhibitor may be needed. However, it is difficult if not impossible to render patients achlorhydric—even on twice-daily doses of proton pump inhibitors—and two-thirds or more of subjects will continue to make acid, particularly at night. This phenomenon, called *nocturnal acid breakthrough*, has been invoked as a cause of refractory symptoms in some patients with GERD. However, decreases in gastric pH at night while on therapy generally are not associated with acid reflux into the esophagus, and the rationale for suppressing nocturnal acid secretion (even if feasible) remains to be established. Nevertheless, patients with continuing symptoms on twice-daily proton pump inhibitors are often treated by adding an  $H_2$  receptor antagonist at night. While this can further suppress acid production, the effect is short-lived, probably due to the development of tolerance, as described above (Fackler *et al.*, 2002).

**Therapy for Extraintestinal Manifestations of GERD.** With varying levels of evidence, acid reflux has been implicated in a variety of atypical symptoms, including noncardiac chest pain, asthma, laryngitis, chronic cough, and other ear, nose, and throat conditions. Proton pump inhibitors have been used with some success in certain patients with these disorders, generally in higher doses and for longer periods of time than those used for patients with more classic symptoms of GERD.

**GERD and Pregnancy.** Heartburn is estimated to occur in 30% to 50% of pregnancies, with an incidence approaching 80% in some populations (Richter, 2003). In the vast majority of cases, GERD ends soon after delivery and thus does not represent an exacerbation of a preexisting condition. Nevertheless, because of its high prevalence and the fact that it can contribute to the nausea of pregnancy, treatment often is required. Treatment choice in this setting is complicated by the paucity of data for the most commonly used drugs. In general, most drugs used to treat GERD fall in FDA Category B, with the exception of omeprazole (FDA Category C).

Mild cases of GERD during pregnancy should be treated conservatively; antacids or sucralfate are considered the first-line drugs. If symptoms persist,  $H_2$  receptor antagonists can be used, with ranitidine having the most established track record in this setting. Proton pump inhibitors are reserved for women with intractable symptoms or complicated reflux disease. In these situations, lansoprazole is considered the preferred choice among the proton pump inhibitors, based on animal data and available experience in pregnant women.

## Peptic Ulcer Disease

The pathophysiology of peptic ulcer disease is best viewed as an imbalance between mucosal defense factors (bicarbonate, mucin, prostaglandin, nitric oxide, and other peptides and growth factors) and injurious factors (acid and pepsin). On average, patients with duodenal ulcers produce more acid than do control subjects, particularly at night (basal secretion). Although patients with gastric ulcers have normal or even diminished acid production, ulcers rarely if ever occur in the complete absence of acid. Presumably, a weakened mucosal defense and reduced bicarbonate production

## Section VI / Drugs Affecting Gastrointest

contribute to the injury from the relatively low levels of acid in these patients. *H. pylori* and exogenous factors such as nonsteroidal antiinflammatory drugs can interact in complex ways to cause an ulcer. Most cases of peptic ulcers are associated with *H. pylori* infection of the stomach. This infection may lead to increased production of somatostatin by D cells, and in turn to inhibition of gastrin production, resulting in decreased acid production and reduced duodenal acid production.

NSAIDs also are very frequently associated with peptic ulcers (in up to 60% of patients, particularly with complications such as bleeding). Topical administration of the drug appears to have a role in the pathogenesis of these ulcers, as evidenced by the fact that ulcers can occur with very low doses of aspirin (10 mg) or with parenteral administration of NSAIDs. The effects of these drugs are instead mediated centrally; the critical element is suppression of the active form of cyclooxygenase-1 (COX-1) in the gastric mucosa and decreased production of the cytoprotective prostaglandins PGE<sub>2</sub> and PGI<sub>2</sub>.

Table 36-4 summarizes current recommendations for drug therapy of gastroduodenal ulcers. Proton pump inhibitors relieve symptoms of duodenal ulcers and promote healing more rapidly than do  $H_2$  receptor antagonists, although both classes of drugs are very effective in this setting. Peptic ulcer represents a chronic condition, and recurrence within 1 year is expected in up to 50% of patients who do not receive prophylactic therapy. With the appreciation that *H. pylori* has a major etiopathogenic role in the majority of peptic ulcers (see below), prevention of relapse is best achieved by eliminating this organism from the stomach. Acid suppression, once the mainstay of ulcer therapy, now is used mainly in patients who are *H. pylori* negative or, in some cases, for maximum prevention of recurrence in patients who have had life-threatening complications.

Intravenous pantoprazole or lansoprazole are preferred therapy in patients with acute bleeding ulcers. The theoretical benefit of maximal acid suppression in this setting is to accelerate healing of the underlying ulcer. In addition, a higher gastric pH enhances clot formation and retards clot dissolution.

**Treatment of Helicobacter pylori Infection.** *Helicobacter pylori*, a gram-negative rod, has been associated with chronic gastritis and the subsequent development of gastric ulcers, gastric adenocarcinoma, and gastric lymphoma (Suerbaum and Michetti, 2002). Bec

## Therapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease

979

## Treatment of Gastroduodenal Ulcers

## ACTIVE ULCER

## MAINTENANCE THERAPY

800 mg at bedtime/400 mg twice daily  
40 mg at bedtime

400 mg at bedtime  
20 mg at bedtime

300 mg after evening meal or at bedtime/150 mg twice daily

150 mg at bedtime

15 mg (DU; NSAID risk reduction) daily  
30 mg (GU including NSAID-associated) daily  
20 mg daily  
20 mg daily

200 µg four times daily (NSAID-associated ulcer prevention)\*

\*Only misoprostol 800 µg/day has been directly shown to reduce the risk of ulcer complications such as perforation (Rostom *et al.*, 2004).

*Helicobacter pylori* in the pathogenesis of peptic ulcers. Eradication of this infection is standard care in the treatment of gastric or duodenal ulcers. Provided that patients are not taking NSAIDs, this strategy almost completely eliminates the risk of ulcer recurrence. Eradication of *H. pylori* is also indicated in the treatment of mucosa-associated lymphoid tissue lymphomas of the stomach; the risk of lymphoma is significantly reduced after such treatment. Several regimens for *H. pylori* eradication have been evaluated. A recent evidence-based literature review suggests that a 14-day regimen in this setting should achieve a cure rate of 90%. Five important considerations influence the choice of an eradication regimen (Graham, 2004; Graham *et al.*, 2005). First, single-antibiotic regimens are ineffective in eradicating *H. pylori* infection and lead to resistance. Combination therapy with two or three antibiotics (plus acid-suppressive therapy) is associated with the highest rate of *H. pylori* eradication. Second, the use of a proton pump inhibitor or H<sub>2</sub> receptor antagonist enhances the effectiveness of *H. pylori* eradication. Third, regimens containing amoxicillin or clarithromycin are more effective than regimens of 10 to 14 days of treatment. Fourth, a 14-day course of therapy generally achieves higher cure rates than shorter treatment regimens; in contrast, poor patient compliance is linked to lower cure rates. Finally, non-related side effects experienced by as many as 20% of patients taking triple-agent regimens, the inconvenience of three- or four-drug regimens requiring several times per day. Packaging that combines all drugs into one convenient unit is available

and may improve patient compliance (Table 36-5). Finally, the emergence of resistance to clarithromycin and metronidazole increasingly is recognized as an important factor in the failure to eradicate *H. pylori*. Clarithromycin resistance is related to mutations that prevent binding of the antibiotic to the ribosomes of the pathogen and is an all-or-none phenomenon. In contrast, metronidazole resistance is relative rather than absolute and may involve several adaptations by the bacteria. In the presence of *in vitro* evidence of resistance to metronidazole, amoxicillin should be used instead. In areas with a high frequency of resistance to clarithromycin and metronidazole, a 14-day, quadruple-drug regimen (three antibiotics combined with a proton pump inhibitor) generally is effective therapy.

**NSAID-Related Ulcers.** Chronic NSAID users have a 2% to 4% risk of developing a symptomatic ulcer, gastrointestinal bleeding, or perforation. Ideally, NSAIDs should be discontinued in patients with an ulcer if at all possible. If continued therapy is needed, selective COX-2 inhibitors may be considered, although this does not eliminate the risk of subsequent ulcer formation and the possible association of these drugs with adverse cardiovascular events mandates caution (see Chapter 25). Healing of ulcers despite continued NSAID use is possible with the use of acid-suppressant agents, usually at higher doses and for a considerably longer duration than standard regimens (e.g., 8 weeks or longer). Again, proton pump inhibitors are superior to H<sub>2</sub> receptor antagonists and misoprostol in promoting the healing of active ulcers (healing rates of 80% to 90% for proton pump inhibitors versus 60% to 75% for the H<sub>2</sub> receptor antagonists), and in preventing recurrence of gastric and duodenal ulcers in the setting of continued NSAID administration (Lanza, 1998).



**Table 36-5****Therapy of *Helicobacter pylori* Infection**

**Triple therapy × 14 days:** [Proton pump inhibitor + clarithromycin 500 mg + (metronidazole 500 mg or amoxicillin 1 g)] twice a day. (Tetracycline 500 mg can be substituted for amoxicillin or metronidazole.)

**Quadruple therapy × 14 days:** Proton pump inhibitor twice a day + metronidazole 500 mg three times daily + (bismuth subsalicylate 525 mg + tetracycline 500 mg four times daily)

or

**H<sub>2</sub> receptor antagonist twice a day + (bismuth subsalicylate 525 mg + metronidazole 250 mg + tetracycline 500 mg) four times daily**

**Dosages:**

Proton pump inhibitors:

Omeprazole: 20 mg

Lansoprazole: 30 mg

Rabeprazole: 20 mg

Pantoprazole: 40 mg

Esomeprazole: 40 mg

H<sub>2</sub> receptor antagonists:

Cimetidine: 400 mg

Famotidine: 20 mg

Nizatidine: 150 mg

Ranitidine: 150 mg

See Howden and Hunt, 1998.

**Stress-Related Ulcers.** Stress ulcers are ulcers of the stomach or duodenum that occur in the context of a profound illness or trauma requiring intensive care. The etiology of stress-related ulcers differs somewhat from that of other peptic ulcers, involving acid and mucosal ischemia. Because of limitations on the oral administration of drugs in many patients with stress-related ulcers, intravenous H<sub>2</sub> receptor antagonists have been used extensively to reduce the incidence of GI hemorrhage due to stress ulcers. Now that intravenous preparations of proton pump inhibitors are available, it is likely that they will prove to be equally beneficial. However, there is some concern over the risk of pneumonia secondary to gastric colonization by bacteria in an alkaline milieu. In this setting, sucralfate appears to provide reasonable prophylaxis against bleeding without increasing the risk of aspiration pneumonia. This approach also appears to provide reasonable prophylaxis against bleeding, but is less convenient (Cook *et al.*, 1998).

**Zollinger-Ellison Syndrome.** Patients with this syndrome develop pancreatic or duodenal gastrinomas that stimulate the secretion of very large amounts of acid, sometimes in the setting of multiple endocrine neoplasia, type I. This can lead to severe gastroduodenal ulceration and other consequences of uncontrolled hyperchlorhydria. Proton pump inhibitors clearly are the drugs of choice, usually given at twice the routine dosage for peptic ulcers with the therapeutic goal of reducing acid secretion to 1 to 10 mmol/h.

**Nonulcer Dyspepsia.** This term refers to ulcer-like symptoms in patients who lack overt gastroduodenal ulceration. It may be associated with gastritis (with or without *H. pylori*) or with NSAID use, but the pathogenesis of this syndrome remains controversial.

**Section VI / Drugs Affecting Gastrointestinal Motility**

Although empirical treatment with acid-suppressants is routinely in patients with nonulcer dyspepsia, the evidence of their benefit in controlled trials.

**CLINICAL SUMMARY**

The control of acid-peptic disease represents a triumph for modern pharmacology. Proton pump inhibitors are considered superior for acid suppression in significant acid-peptic diseases, including gastroesophageal reflux disease, peptic ulcers, and NSAID-induced ulcers. Proton pump inhibitors also are employed with antibiotics to eradicate infection with *H. pylori*, thereby play a role in preventing recurrent ulcers. These agents largely have replaced the use of H<sub>2</sub> receptor antagonists and sucralfate, although the latter still is a logical alternative for prophylaxis against stress ulcers. The maximal inhibition of acid secretion with the proton pump inhibitors (3 to 5 days) makes them less suited for as-needed basis for symptom relief. In this setting, H<sub>2</sub> receptor antagonists, while less effective than proton pump inhibitors in suppressing acid secretion, have a more rapid onset of action that makes them useful for patient management of mild or infrequent symptoms.

**BIBLIOGRAPHY**

- Black, J. Reflections on the analytical pharmacology of H<sub>2</sub> receptor antagonists. *Gastroenterology*, 1993, 105:98-105.
- Chong, B., and Ensom, M.H. Pharmacogenetics of proton pump inhibitors: a systematic review. *Pharmacotherapy*, 2003, 23:100-110.
- Cook, D., Guyatt, G., Marshall, J., *et al.* Comparison of ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Group. *N. Engl. J. Med.*, 1998, 338:791-797.
- Dickson, B.J., and Stuart, R.C. Genetics of response to proton pump inhibitor therapy: clinical implications. *Am. J. Pharmacotherapy*, 2003, 3:303-315.
- Fackler, W.K., Ours, T.M., Vaezi, M.F., and Richter, J.C. Effect of H<sub>2</sub>RA therapy on nocturnal gastric acid secretion. *Gastroenterology*, 2002, 122:625-632.
- Freston, J., Chiu, Y.L., Pan, W.J., Lukasik, N., and Tedlow, R. Availability of pantoprazole suspended in sodium bicarbonate solution. *Am. J. Health Syst. Pharm.*, 2003, 60:1324-1329.
- Graham, D.Y. Therapy of *Helicobacter pylori*: current status. *Gastroenterology*, 2000, 118:S2-S8.
- Howden, C.W., and Hunt, R.H. Guidelines for the management of *Helicobacter pylori* infection. Ad Hoc Committee on the Management of *Helicobacter pylori* Infection. *Am. J. Gastroenterol.*, 1998, 93:2330-2338.
- Klinkenberg-Knol, E.C., Festen, H.P., Jansen, J.B., *et al.* Treatment with omeprazole for refractory esophagitis: safety. *Ann. Intern. Med.*, 1994, 121:161-167.



## Milestones in Drug Therapy

Michael J. Parnham

Jacques Bruinvels


Series Editors

# Macrolide Antibiotics

W. Schönfeld

H. A. Kirst

Editors



Birkhäuser

M.-T. Labro

bone marrow-  
l drugs undero activities of  
id amikacin in  
3-749.  
s avium withinpharmacologic  
x infection inof granulocyte  
ant *Mycobac-*  
r 37: 692-695.  
alar accumula-71002  
1999 *In vitro*  
*ntisia tsutsuga-*  
2410ceptibilities of  
*L. akari*, and *R.*  
dy analysis ofHof H' (1998)  
idrug resistantcellular killing  
l macrophages

omycin against

of antibiotics  
in a model of  
onf Antimicrobhromycylamine  
54rotects virulent  
: 2802Macrolide Antibiotics  
ed. by W. Schönfeld and H. A. Kört  
© 2002 Birkhäuser Verlag Basel/Switzerland

53

## Clarithromycin and new derivatives of erythromycin


Takashi Adachi and Shigeo Morimoto

Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 403 Yoshino-cho 1-chome,  
Saitama-shi, Saitama 330-8530, Japan

### Introduction

Since erythromycin's the discovery in 1952 [1], it has been one of the most useful macrolide antibiotics, having the highest antibacterial activity and low toxicity. In order to achieve high antibacterial activities against a wide variety of pathogens and favorable pharmacokinetic properties, tremendous efforts have been made related to chemical modification [2, 3]. In the 1970s and 1980s, dirithromycin, flurithromycin, and davercin were synthesized and evaluated. Erythromycin itself is quite unstable under acidic conditions, so esters, salts, and various formulations also have been developed.

At Taisho Pharmaceutical Co. Ltd., we were interested in the role of the hydroxyl groups of erythromycin (2), and a series of *O*-alkylated derivatives was synthesized [4-8]. Among them, clarithromycin (6-*O*-methylerythromycin A, 1) exhibited antibacterial activities against aerobic gram-positive bacteria, some gram-negative bacteria, anaerobic bacteria, *Mycoplasma*, and *Chlamydia*. The antibacterial activities of clarithromycin were equal to or two-fold better than erythromycin A (2) *in vitro*. However, clarithromycin is fairly stable in acidic conditions due to 6-*O*-methylation, which brought about excellent biological properties, especially *in vivo* antibacterial activities, pharmacokinetic properties, and metabolism. The structural difference between clarithromycin and erythromycin is only the 6-*O*-methyl group, but the biological properties of clarithromycin were improved considerably.



Clarithromycin (1) R=CH<sub>3</sub>  
Erythromycin A (2) R=H

Figure 1. Structures of clarithromycin (1) and erythromycin A (2).

Additional clinical applications of clarithromycin for the treatment of mycobacterial infections and *Helicobacter pylori*-associated gastroduodenal disease have been approved. Disseminated *Mycobacterium avium* complex (MAC) infection is a common opportunistic disease in AIDS patients and is associated with significant morbidity and mortality. Clarithromycin, having strong antibacterial activities against this pathogen, is useful for the treatment and prevention of MAC infections [45-47]. Clarithromycin has been used for treatment and prevention of the recurrence of gastroduodenal ulcers caused by *H. pylori* by combination therapy with  $\beta$ -lactam antibiotics and proton pump inhibitors. The strong antibacterial activity of clarithromycin against *H. pylori* and high acid stability are thought to contribute to the efficacy [48-51].

Long-term administration of erythromycin as well as clarithromycin is useful for the treatment of diffuse panbronchiolitis (DPB). DPB is a disease characterized by chronic inflammation of the respiratory bronchioles and the infiltration of chronic inflammatory cells. The disease results in respiratory failure due to infection by *Pseudomonas aeruginosa* or *H. influenzae* and was previously difficult to treat. The efficacy of erythromycin for this disease was reported in 1987 [52]. Erythromycin and clarithromycin do not show antibacterial activity against *P. aeruginosa*, but they do improve pulmonary functions [53]. Efficacy of 16-membered macrolides has not been reported.

The mechanism of 14-membered macrolides in DPB has been investigated, and new biological properties of macrolides have been revealed. For example, erythromycin inhibited respiratory glycoconjugate secretion [54] and chloride secretion across canine tracheal cells [55]. The number of neutrophils and the neutrophil-derived elastolytic-like activity in bronchoalveolar lavage fluid decreased after treatment with erythromycin along with a significant improvement in pulmonary function [56]. Erythromycin inhibited intrapulmonary influx of neutrophils in mice with intratracheal injection of recombinant IL-8 [57]. Erythromycin suppressed the proliferation of lymphocytes [58] and promoted differentiation of monocytes to macrophages [59]. Many pathogens produce glycocalyx and form biofilm. Erythromycin and clarithromycin degraded the biofilm, which may be related to the efficacy in the treatment of DPB [60].

#### Recent chemical modification of erythromycin

In the early 1990s, three new macrolides, clarithromycin, roxithromycin, and azithromycin, were developed, and they have expanded the indications of this class of drug into new therapeutic areas. For further improvement of erythromycin derivatives, macrolide resistant *S. pneumoniae* and *H. influenzae* have been regarded as key pathogens.

At Taisho Pharmaceutical Co., Ltd., chemical modification has been continued and a new class of macrolides has been synthesized (Fig. 4).

TE-802 (32), a 9,11,12-tricyclic ketolide, exhibited strong *in vitro* antibacterial activities against both erythromycin-susceptible bacteria and erythromycin-resis-

Ch

O

O

Fig

Ta

ta)

S.

cli

ac

m

sq

sy

Ti

tin

be

- 40 Olsson-Liljequist B, Hoffman BM (1991) *In-vitro* activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against *Haemophilus influenzae*. *J Antimicrob Chemother* 27(Suppl. A): 11-17
- 41 Sasaki J, Mizoue K, Morimoto S, Adachi T (1988) Microbial transformation of 6-O-methylerythromycin derivatives. *J Antibiot* 41: 908-915
- 42 Adachi T, Sasaki J, Omura S (1989) Hydroxylation and N-demethylation of clarithromycin (6-O-methylerythromycin A) by *Mucor circinaloides*. *J. Antibiot* 42: 1433-1437
- 43 Finch RG (1997) Overview of the clinical use of macrolides and streptogramins. *Infect Dis Ther* 1997: 3-26
- 44 Langtry HD, Brogden RN (1997) Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. *Drugs* 53: 973-1004
- 45 Turtaglione TA (1996) Therapeutic options for the management and prevention of *Mycobacterium avium* complex infection in patients with the acquired immunodeficiency syndrome. *Pharmacother* 16: 171-182
- 46 Merti SL (1996) The role of clarithromycin in the prophylaxis of disseminated *Mycobacterium avium-intracellulare* infection in patients with AIDS. *Pharmacother* 16: 393-400
- 47 Wright J (1998) Current strategies for the prevention and treatment of disseminated *Mycobacterium avium* complex infection in patients with AIDS. *Pharmacother* 18: 738-747
- 48 Markham A, McTavish D (1996) Clarithromycin and omeprazole in *Helicobacter pylori* eradication therapy in patients with *H. pylori*-associated gastric disorders. *Drugs* 51: 161-178
- 49 NIH consensus development panel on *Helicobacter pylori* in peptic ulcer disease (1994) *Helicobacter pylori* in peptic ulcer disease. *JAMA* 272: 65-69
- 50 Soll AH (1996) Medical treatment of peptic ulcer disease: Practical guidelines. *JAMA* 275: 622-629
- 51 The European *Helicobacter pylori* study group (1997) Current European concepts in the management of *Helicobacter pylori* infection: The Maastricht Consensus Report. *Gut* 41: 8-13
- 52 Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus L, Kimura H, Sugiyama Y (1987) Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. *Jpn J Thorac Dis* 25: 632-642
- 53 Sawaki M, Mikasa K, Konishi M, Maeda K, Narita N (1998) Clinical study of long-term treatment using erythromycin in chronic lower respiratory tract infection. *Jpn J Chemother* 46: 239-247
- 54 Gaswami SK, Kivity S, Muroin Z (1990) Erythromycin inhibits respiratory glycoconjugate secretion from human airways *in vitro*. *Am Rev Respir Dis* 141: 72-78
- 55 Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K (1992) Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. *Eur Respir J* 5: 234-238
- 56 Ichikawa Y, Ninomiya H, Koga H, Tanaka M, Kinoshita M, Tokunaga N, Yano T, Oizumi K (1992) Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. *Am Rev Respir Dis* 146: 196-203
- 57 Kadota J, Sakito O, Kohno S, Sawa H, Mukae H, Oda H, Kawakami K, Fukushima K, Hiratani K, Hara K (1993) A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. *Am Rev Respir Dis* 147: 153-159
- 58 Keicho N, Kudoh S, Yotsumoto H, Akagawa KS (1993) Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin. *J Antibiot* 46: 1406-1413
- 59 Keicho N, Kudoh S, Yotsumoto H, Akagawa KS (1993) Erythromycin promotes monocyte to macrophage differentiation. *J Antibiot* 47: 80-89
- 60 Takeda H, Ohotami H, Ohgaki N (1994) Basic action of macrolide to diffuse panbronchiolitis. *Antibiot Chemother* 10: 1305-1312
- 61 Kashimura M, Asaka T, Misawa Y, Matsumoto K, Morimoto S (2001) Synthesis and antibacterial activity of the tricyclic ketolides TE-802 and its analogs. *J Antibiot* 54: 664-678
- 62 Asaka T, Kashimura M, Ishii T, Matsura A, Suzuki K, Ohyauchi R, Matsumoto K, Numata K, T, Akashi T, Adachi T, Morimoto S (1997) New macrolide antibiotics, acylides (3-O-acyl-5-O-deoxosaminylerythronolides): Synthesis and biological properties. 37<sup>th</sup> ICAAC, Toronto, Canada, Abstract F-262
- 63 Asaka T, Kashimura M, Manaka A, Tanikawa T, Ishii T, Sugimoto T, Suzuki K, Sugiyama H, Akashi T, Saito H, Adachi T, Morimoto S (1999) Structure activity studies leading potent

**Pamela Korzeniowski**

---

**From:** Pamela Korzeniowski [pkorzeniowski@dpeterhochberg.com]  
**Sent:** Thursday, June 25, 2009 10:27 AM  
**To:** 'office@kopas.at'  
**Subject:** Safe Receipt Confirmation of Letter

Letter Fax Date: June 25, 2009

• Your Ref. 9277

• Our Ref. KS4255US (#90711)

• This email confirms safe receipt of the above referenced fax.

Pamela Korzeniowski  
D. Peter Hochberg Co., L.P.A.  
1940 East 6th Street, Sixth Floor  
Cleveland, OH 44114  
Phone: 216.771.3800  
• Fax: 216.771.3804  
• Email: [pkorzeniowski@dpeterhochberg.com](mailto:pkorzeniowski@dpeterhochberg.com)  
• Website: [www.dpeterhochberg.com](http://www.dpeterhochberg.com)